Title: Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India
| dc.contributor.author | Upinder Kaur | |
| dc.contributor.author | Sapna Bala | |
| dc.contributor.author | Aditi Joshi | |
| dc.contributor.author | Noti Taruni Srija Reddy | |
| dc.contributor.author | Chetan Japur | |
| dc.contributor.author | Mayank Chauhan | |
| dc.contributor.author | Nikitha Pedapanga | |
| dc.contributor.author | Shubham Kumar | |
| dc.contributor.author | Anurup Mukherjee | |
| dc.contributor.author | Vaibhav Mishra | |
| dc.contributor.author | Dolly Talda | |
| dc.contributor.author | Rohit Singh | |
| dc.contributor.author | Rohit Kumar Gupta | |
| dc.contributor.author | Ashish Kumar Yadav | |
| dc.contributor.author | Poonam Jyoti Rana | |
| dc.contributor.author | Jyoti Srivastava | |
| dc.contributor.author | Shobha Bhat K | |
| dc.contributor.author | Anup Singh | |
| dc.contributor.author | G. Naveen Kumar P. | |
| dc.contributor.author | Manoj Pandey | |
| dc.contributor.author | Kishor Patwardhan | |
| dc.contributor.author | Sangeeta Kansal | |
| dc.contributor.author | Sankha Shubhra Chakrabarti | |
| dc.date.accessioned | 2026-02-07T11:00:33Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Background There is paucity of real-world data on COVID-19 vaccine effectiveness from cohort designs. Variable vaccine performance has been observed in test-negative case-control designs. There is also scarce real-world data of health issues in individuals receiving vaccines after prior COVID-19, and of adverse events of significant concern (AESCs) in the vaccinated. Methods: A cohort study was conducted from July 2021 to December 2021 in a tertiary hospital of North India. The primary outcome was vaccine effectiveness against COVID-19 during the second wave in India. Secondary outcomes were AESCs, and persistent health issues in those receiving COVID-19 vaccines. Regression analyses were performed to determine risk factors of COVID-19 outcomes and persistent health issues. Results: Of the 2760 health care workers included, 2544 had received COVID-19 vaccines, with COVISHIELD (rChAdOx1-nCoV-19 vaccine) received by 2476 (97.3%) and COVAXIN (inactivated SARS-CoV-2 vaccine) by 64 (2.5%). A total of 2691 HCWs were included in the vaccine effectiveness analysis, and 973 COVID-19 events were reported during the period of analysis. Maximum effectiveness of two doses of vaccine in preventing COVID-19 occurrence was 17% across three different strategies of analysis adopted for robustness of data. One-dose recipients were at 1.27-times increased risk of COVID-19. Prior SARS-CoV-2 infection was a strong independent protective factor against COVID-19 (aOR 0.66). Full vaccination reduced moderate–severe COVID-19 by 57%. Those with lung disease were at 2.54-times increased risk of moderate–severe COVID-19, independent of vaccination status. AESCs were observed in 33/2544 (1.3%) vaccinees, including one case each of myocarditis and severe hypersensitivity. Individuals with hypothyroidism were at 5-times higher risk and those receiving a vaccine after recovery from COVID-19 were at 3-times higher risk of persistent health issues. Conclusions: COVID-19 vaccination reduced COVID-19 severity but offered marginal protection against occurrence. The possible relationship of asthma and hypothyroidism with COVID-19 outcomes necessitates focused research. With independent protection of SARS-CoV-2 infection, and high-risk of persistent health issues in individuals receiving vaccine after recovery from SARS-CoV-2 infection, the recommendation of vaccinating those with prior SARS-CoV-2 infection needs reconsideration. © 2022 by the authors. | |
| dc.identifier.doi | 10.3390/vaccines10071153 | |
| dc.identifier.issn | 2076393X | |
| dc.identifier.uri | https://doi.org/10.3390/vaccines10071153 | |
| dc.identifier.uri | https://dl.bhu.ac.in/bhuir/handle/123456789/41111 | |
| dc.publisher | MDPI | |
| dc.subject | adverse events following immunization | |
| dc.subject | asthma | |
| dc.subject | hypothyroidism | |
| dc.subject | inflammatory arthritis | |
| dc.subject | long COVID | |
| dc.subject | myocarditis | |
| dc.subject | pharmacovigilance | |
| dc.subject | RAAS blockers | |
| dc.title | Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India | |
| dc.type | Publication | |
| dspace.entity.type | Article |
